Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

v3.7.0.1
Accrued expenses and other current liabilities
 6 Months Ended
Jun. 30, 2017
Accrued expenses and other current liabilities  
Accrued expenses and other current liabilities

 

Note 8 — Accrued expenses and other current liabilities

 

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

June 30,
2017

 

December 31,
2016

 

Clinical & Development Accruals

 

$
5,698

 

$
4,938

 

Accued employee expenses

 
4,150

 
4,539

 

Accrued capital expenditure

 
908

 
3,954

 

VAT

 

—

 
2,014

 

Accrued expenses

 
2,188

 
1,003

 

Other

 
428

 
1,080

 

 

 

 

 

 

 

 

 

$
13,372

 

$
17,528

 

 

 

 

 

 

 

 

 

 

The Company typically has a receivable for VAT.  As of December 31, 2016 there was a VAT payable due to VAT arising on the milestone payments invoiced to GSK in 2016.